Literature DB >> 25426655

A field evaluation of a new molecular-based point-of-care test for chlamydia and gonorrhoea in remote Aboriginal health services in Australia.

Louise M Causer1, Belinda Hengel1, Lisa Natoli1, Annie Tangey1, Steven G Badman1, Sepehr N Tabrizi2, David Whiley3, James Ward1, John M Kaldor1, Rebecca J Guy1.   

Abstract

UNLABELLED: Background Point-of-care (POC) tests could be important public health tools in settings with treatment delays and high rates of sexually transmissible infections (STIs). Use is limited due to suboptimal performance. The performance and ease-of-use of a new molecular-based POC test for simultaneous detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) was assessed, alongside two single-organism immunochromatographic tests (ICT).
METHODS: The evaluation occurred between May 2012 and March 2013 during community STI screens in two remote Aboriginal health services. Urine was tested with the GeneXpert(®)CT/NG and if sufficient volume, also with Diaquick CT and Gonorrhoea Card. The gold standard comparison was laboratory nucleic acid amplification testing (NAAT). Operational characteristics were also assessed.
RESULTS: Among 198 samples, GeneXpert CT sensitivity and specificity was 100% [95% confidence intervals (CI): 75.9-100] and 99.5% (95% CI: 96.5-100), and NG was 100% (95% CI: 96.5-100) and 100% (95% CI: 97.5-100), respectively. Among a sample subset, Diaquick CT (n=104) sensitivity and specificity was 27.3% (95% CI: 7.3-60.7) and 66.7% (95% CI: 12.5-98.2), and Gonorrhoea Card (n=29), was 66.7% (95% CI: 12.5-98.2) and 76.9% (95% CI: 56.0-90.2), respectively. GeneXpert required 1mL of urine, four steps, 1min specimen preparation and 90min to result. ICTs required 15mL of urine, eight steps, 18min preparation and 10-15min to result.
CONCLUSION: The accuracy and operational benefits of GeneXpert CT/NG make it very suitable in these settings where delays to treatment are encountered.

Entities:  

Year:  2015        PMID: 25426655     DOI: 10.1071/SH14158

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  8 in total

1.  Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003).

Authors:  Zvavahera Mike Chirenje; Holly M Gundacker; Barbra Richardson; Lorna Rabe; Zakir Gaffoor; Gonasagrie Lulu Nair; Brenda Gati Mirembe; Jeanna M Piper; Sharon Hillier; Jeanne Marrazzo
Journal:  Sex Transm Dis       Date:  2017-03       Impact factor: 2.830

2.  Combination with antimicrobial peptide lyses improves loop-mediated isothermal amplification based method for Chlamydia trachomatis detection directly in urine sample.

Authors:  Jekaterina Jevtuševskaja; Julia Uusna; Liis Andresen; Katrin Krõlov; Made Laanpere; Tiia Grellier; Indrek Tulp; Ülo Langel
Journal:  BMC Infect Dis       Date:  2016-07-13       Impact factor: 3.090

3.  "I Do Feel Like a Scientist at Times": A Qualitative Study of the Acceptability of Molecular Point-Of-Care Testing for Chlamydia and Gonorrhoea to Primary Care Professionals in a Remote High STI Burden Setting.

Authors:  Lisa Natoli; Rebecca J Guy; Mark Shephard; Louise Causer; Steven G Badman; Belinda Hengel; Annie Tangey; James Ward; Tony Coburn; David Anderson; John Kaldor; Lisa Maher
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

4.  Leucocyte esterase dip-stick test as a point-of-care diagnostic for urogenital chlamydia in male patients: A multi-center evaluation in two STI outpatient clinics in Paramaribo and Amsterdam.

Authors:  Menne Bartelsman; Henry J C de Vries; Maarten F Schim van der Loeff; Leslie O A Sabajo; Jannie J van der Helm
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

5.  Impact of deploying multiple point-of-care tests with a 'sample first' approach on a sexual health clinical care pathway. A service evaluation.

Authors:  Emma M Harding-Esch; Achyuta V Nori; Aseel Hegazi; Marcus J Pond; Olanike Okolo; Anthony Nardone; Catherine M Lowndes; Phillip Hay; S Tariq Sadiq
Journal:  Sex Transm Infect       Date:  2017-02-03       Impact factor: 3.519

Review 6.  Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential.

Authors:  Stacy G Beal; Naziheh Assarzadegan; Kenneth H Rand
Journal:  Expert Rev Mol Diagn       Date:  2016-01-11       Impact factor: 5.225

Review 7.  Progress and Perspectives in Point of Care Testing for Urogenital Chlamydia trachomatis Infection: A Review.

Authors:  Liang Peng; Jian-Lin Chen; Dao Wang
Journal:  Med Sci Monit       Date:  2020-04-16

8.  Evaluation of the Diagnostic Efficacy of Xpert CT/NG for Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  Tian-Ao Xie; Ye-Ling Liu; Rui-Chun Meng; Xiao-Shan Liu; Ke-Ying Fang; Shu-Ting Deng; Shu-Jin Fan; Chu-Mao Chen; Qin-Rong Lin; Zhi-Jian He; Zhen-Xing Li; Shi Ouyang; Guo-Dong Zhu; Tian-Xing Ji; Yong Xia; Zhi-Yong Pan; Xu-Guang Guo
Journal:  Biomed Res Int       Date:  2020-10-08       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.